JP2516542B2 - Laxative-containing laxative composition - Google Patents

Laxative-containing laxative composition

Info

Publication number
JP2516542B2
JP2516542B2 JP5005064A JP506493A JP2516542B2 JP 2516542 B2 JP2516542 B2 JP 2516542B2 JP 5005064 A JP5005064 A JP 5005064A JP 506493 A JP506493 A JP 506493A JP 2516542 B2 JP2516542 B2 JP 2516542B2
Authority
JP
Japan
Prior art keywords
lactic acid
laxative
seed coat
acid bacteria
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP5005064A
Other languages
Japanese (ja)
Other versions
JPH07173068A (en
Inventor
操 村田
雅 成田
洋一 中嶋
曜 岩佐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SSP Co Ltd
Original Assignee
SSP Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SSP Co Ltd filed Critical SSP Co Ltd
Priority to JP5005064A priority Critical patent/JP2516542B2/en
Publication of JPH07173068A publication Critical patent/JPH07173068A/en
Application granted granted Critical
Publication of JP2516542B2 publication Critical patent/JP2516542B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明はプランタゴ・オバタ種皮
に乳酸菌を安定かつ均質に配合せしめた乳酸菌含有瀉下
薬に関するものである。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a laxative containing lactic acid bacterium in which lactic acid bacterium is stably and homogeneously mixed with plantago ovata seed coat.

【0002】[0002]

【従来の技術】プランタゴ・オバタ種皮は医薬品製造指
針において膨潤性下剤成分として瀉下薬基準に収載され
ているものである。
2. Description of the Related Art Plantago ovata seed coat is listed as a swelling laxative component in the standard of laxatives in the pharmaceutical manufacturing guidelines.

【0003】一方、乳酸菌は整腸生菌成分として瀉下薬
への配合が認められており、デンプン、乳糖、白糖など
適当な賦形剤又はそれらの混合物と混合されており、日
本薬局方外医薬品成分規格にもラクトミンとして収載さ
れているものである。
[0003] On the other hand, lactic acid bacteria have been approved as a component of live intestinal bacteria in laxatives, and have been mixed with suitable excipients such as starch, lactose, sucrose, or a mixture thereof, which is a non-Japanese Pharmacopoeia It is also listed as lactomin in the component specifications.

【0004】したがって、これらの両成分を配合して安
全かつ緩和な瀉下薬を医薬品として供することは有意義
なことである。
Therefore, it is significant to combine these two components and provide a safe and mild laxative as a medicine.

【0005】しかしながら、乳酸菌は一般的な顆粒の製
法である賦形剤等と混合・練合して造粒操作を行うと菌
が死滅するため、乳酸菌に他の瀉下薬有効成分を配合し
た安定性の優れた乳酸菌含有瀉下薬製剤を医薬品として
市場に供することは困難であり、特に、乳酸菌とプラン
タゴ・オバタ種皮を配合したものは無かった。
However, when lactic acid bacteria are mixed and kneaded with an excipient which is a general method for producing granules and the granulation operation is carried out, the bacteria are killed. Therefore, lactic acid bacteria are stably mixed with other active laxatives. It is difficult to put a laxative preparation containing lactic acid bacteria, which has excellent properties, on the market as a drug, and in particular, there has been no combination of lactic acid bacteria and plantago ovata seed coat.

【0006】一方、製造時の乳酸菌の死滅を防ぐために
プランタゴ・オバタ種皮に単に乳酸菌を混合する方法に
より安定な組成物を得ることができると考えられる。し
かしながら、この方法もプランタゴ・オバタ種皮と乳酸
菌の物性の相違が大きいために、単に混合するだけでは
菌の死滅を防ぐことはできても均質な製剤を得ることは
難しく、更に服用感も良くない。しかも、輸送したり分
包剤を製したときに、偏析を生じ医薬品の品質上好まし
くない。また、プランタゴ・オバタ種皮と精製白糖とを
単に造粒したものが知られており、このものに乳酸菌を
混合したものは安定性も高く、服用感も良い。しかしな
がら、このものの表面は微粒子を保持できる程に粗くな
いため、乳酸菌のような微粒子を均質に保持することは
難しく、輸送したり分包剤を製したときに、偏析を生じ
医薬品の品質上好ましくない。
On the other hand, it is considered that a stable composition can be obtained by simply mixing lactic acid bacteria with Plantago ovata seed coat in order to prevent the death of the lactic acid bacteria during production. However, this method also has a large difference in physical properties between plantago ovata seed coat and lactic acid bacterium, so that it is possible to prevent the killing of the bacterium by simply mixing them, but it is difficult to obtain a homogeneous preparation, and the feeling of ingestion is not good either. . Moreover, segregation occurs during transportation or when a packaging material is produced, which is not preferable in terms of the quality of the drug. Further, it is known that plantago ovata seed coat and purified sucrose are simply granulated, and a mixture of this and lactic acid bacteria has high stability and a good feeling to take. However, since the surface of this product is not rough enough to hold fine particles, it is difficult to uniformly hold fine particles such as lactic acid bacteria, and when the product is transported or a packaging material is produced, segregation occurs, which is preferable in terms of pharmaceutical quality. Absent.

【0007】[0007]

【発明が解決しようとする課題】従って、本発明の目的
は、プランタゴ・オバタ種皮に乳酸菌を安定かつ均質に
配合せしめた乳酸菌含有瀉下薬を提供することにある。
SUMMARY OF THE INVENTION Therefore, an object of the present invention is to provide a lactic acid bacterium-containing purgative drug in which lactic acid bacterium is stably and uniformly blended with plantago ovata seed coat.

【0008】[0008]

【課題を解決するための手段】斯かる実情に鑑み本発明
者らは鋭意研究を重ねた結果、プランタゴ・オバタ種皮
の表面に水系溶媒を用いて糖類を付着せしめれば、該表
面が改質され、乳酸菌の付着が容易となり、均質で安定
かつ服用感のよい乳酸菌含有瀉下薬組成物が得られるこ
とを見出し、本発明を完成した。
In view of such circumstances, the inventors of the present invention have conducted extensive studies, and as a result, if sugars were attached to the surface of Plantago ovata seed coat using an aqueous solvent, the surface was modified. Thus, the inventors have found that a lactic acid bacterium-containing cathartic composition which is easy to attach to lactic acid bacterium and is homogeneous, stable, and having a good feeling on ingestion can be obtained.

【0009】すなわち本発明は、プランタゴ・オバタ種
皮表面に、水系溶媒の存在下に糖類を付着せしめて得ら
れた不定形顆粒化物と乳酸菌とを配合してなる瀉下薬組
成物を提供するものである。
That is, the present invention provides a cathartic composition comprising a lactic acid bacterium and an amorphous granule obtained by adhering a saccharide in the presence of an aqueous solvent on the surface of a plantago ovata seed coat. is there.

【0010】本発明に用いる糖類は、内服用に使用でき
るものであれば特に限定されないが、特に白糖、ブドウ
糖、マンニトール、キシリトール、還元麦芽糖、乳糖又
はこれらの混合物を用いると服用感の優れた瀉下薬組成
物を得ることができる。
The saccharide used in the present invention is not particularly limited as long as it can be used for oral administration, but especially when sucrose, glucose, mannitol, xylitol, reduced maltose, lactose or a mixture thereof is used, it has an excellent phlegm feeling. A pharmaceutical composition can be obtained.

【0011】また、本発明において、プランタゴ・オバ
タ種皮表面に糖類を付着せしめる方法としては、例えば
次の方法が例示される。 (1)プランタゴ・オバタ種皮を水系溶媒を加えて湿潤
させた後、糖類を添加して攪拌造粒する方法。 (2)プランタゴ・オバタ種皮と糖類の混合物に水系溶
媒を加え攪拌造粒する方法。 (3)プランタゴ・オバタ種皮を糖類の溶液にて噴霧造
粒する方法。
In the present invention, the following method is exemplified as a method for attaching saccharides to the surface of the planta ovata seed coat. (1) A method in which an aqueous solvent is added to a plantago ovata seed coat to moisten it, and then saccharides are added to the granules with stirring. (2) A method in which an aqueous solvent is added to a mixture of plantago-Obata seed coat and saccharides and the mixture is stirred and granulated. (3) A method of spray granulating plantago and ovata seed coats with a saccharide solution.

【0012】プランタゴ・オバタ種皮に付着させる糖類
の量は、糖類の種類によっても異なるが、プランタゴ・
オバタ1重量部に対し糖類を20〜200重量%付着さ
せることが好ましい。
[0012] The amount of sugar attached to the seed coat of plantago ovata varies depending on the type of sugar.
It is preferable to add 20 to 200% by weight of saccharides to 1 part by weight of ovata.

【0013】このように種皮に糖類を付着させた後、必
要により、乾燥、整粒等を行う。得られた不定形顆粒化
物は、粗面を有するため微粒子を保持しやすくなってお
り、乳酸菌を混ぜるだけで、或いは不定形顆粒化物を僅
かに湿潤させた後、乳酸菌と混合することにより、安定
性が高く、均質性に優れ、更に服用感のよい乳酸菌含有
瀉下薬組成物を得ることができる。
After the saccharides have been attached to the seed coat in this way, if necessary, drying, sizing and the like are performed. The obtained irregularly shaped granules have a roughened surface, which makes it easy to retain fine particles.Stable by simply mixing lactic acid bacteria or slightly moistening the irregularly shaped granules and then mixing with lactic acid bacteria, It is possible to obtain a laxative composition containing a lactic acid bacterium, which is highly effective, has excellent homogeneity, and has a good feeling of ingestion.

【0014】乳酸菌の混合方法は不定形顆粒化物に、乳
酸菌を加えて混合機で混合するだけでもよいが、不定形
顆粒化物に水を噴霧して僅かに湿潤させた後、乳酸菌を
加えて混合機で混合し、ただちに乾燥させる方法がより
好ましい。
The lactic acid bacterium may be mixed by adding the lactic acid bacterium to the amorphous granule and mixing them with a mixer. However, the irregular granule is sprayed with water to slightly wet it, and then the lactic acid bacterium is added and mixed. More preferable is a method of mixing by a machine and immediately drying.

【0015】かくして得られる本発明組成物はフレーク
状の粒及び細片の形状を有しており、そのまま医薬製剤
として利用できるが、更にこれに生薬の健胃成分やビタ
ミンB6 、ニコチン酸アミド等のビタミン類を加えて瀉
下薬としての有用性を高めることができる。また、矯味
剤や賦形剤等を配合し、顆粒、用時調製の液剤等として
利用することもできる。
The composition of the present invention thus obtained has the shape of flakes and particles and can be used as it is as a pharmaceutical preparation. In addition to this, a stomachic ingredient of crude drug, vitamin B 6 and nicotinic acid amide are further added. It is possible to enhance the usefulness as a cathartic by adding vitamins such as. It is also possible to add a corrigent, an excipient, etc., and use it as a granule, a liquid preparation prepared at the time of use, or the like.

【0016】[0016]

【発明の効果】本発明の瀉下薬組成物は、プランタゴ・
オバタ種皮の表面が糖類により粗面となっているため、
乳酸菌が安定に保持されており、分包しても偏析は少な
く、安定で均質な製剤である。更に本発明の組成物はフ
レーク状の粒及び細片の形状を有しており、歯ざわりが
よく極めて服用感に優れているため、コンプライアンス
の改善に寄与するものである。
The laxative composition of the present invention comprises plantago
Since the surface of ovata seed coat is roughened by sugar,
The lactic acid bacterium is stably retained, and even if it is packaged, segregation is small, and the formulation is stable and homogeneous. Furthermore, the composition of the present invention has the shape of flake-shaped particles and strips, has a good texture and is extremely excellent in ingestion, and thus contributes to the improvement of compliance.

【0017】[0017]

【実施例】以下、実施例を挙げて本発明を詳細に説明す
るが、本発明はこれらに限定されるものではない。以
下、実施例1〜3、比較例1〜2に示す如き乳酸菌含有
瀉下薬組成物を製造した。なお、乳酸菌はビオヂアスミ
ンF−100(天野製薬(株)製、1g中乳酸菌140
×108 個含む)を用いた。
The present invention will be described in detail below with reference to examples, but the present invention is not limited thereto. Hereinafter, laxative compositions containing lactic acid bacteria were produced as shown in Examples 1 to 3 and Comparative Examples 1 and 2. In addition, lactic acid bacterium is Biodiasmin F-100 (manufactured by Amano Pharmaceutical Co., Ltd.)
X10 8 pieces were used).

【0018】実施例1 プランタゴ・オバタ種皮350gを造粒機(パウレック
(株)製、FM−VG10型バーチカルグラニュレータ
ー)にとり、水50mlを加えて湿潤させた後、精製白糖
250g加えて攪拌造粒し、乾燥した後、整粒し、不定
形顆粒化物540gを得た。この不定形顆粒化物60g
にビオヂアスミンF−100 0.6gを加えて混合
し、乳酸菌含有瀉下薬組成物を得た。
Example 1 350 g of plantago ovata seed coat was placed in a granulator (manufactured by Paulec Co., Ltd., FM-VG10 type vertical granulator), 50 ml of water was added to moisten the mixture, and 250 g of purified sucrose was added to the granulation with stirring. After drying and drying, the particles were sized to obtain 540 g of an irregular granule. 60g of this irregular shaped granule
0.6 g of biodiasmin F-100 was added to and mixed with the mixture to obtain a laxative composition containing lactic acid bacteria.

【0019】実施例2 プランタゴ・オバタ種皮350g及び精製白糖250g
を造粒機(パウレック(株)製、FM−VG10型バー
チカルグラニュレーター)にとり、水40mlを加えて攪
拌造粒し、乾燥した後、整粒し、不定形顆粒化物560
gを得た。この不定形顆粒化物60gにビオヂアスミン
F−100を0.6g加えて混合し、乳酸菌含有瀉下薬
組成物を得た。
Example 2 350 g of plantago ovata seed coat and 250 g of refined white sugar
Was placed in a granulator (manufactured by Paulec Co., Ltd., FM-VG10 type vertical granulator), 40 ml of water was added, and the mixture was granulated by stirring, dried, and then sized to give an amorphous granule 560.
g was obtained. To 60 g of this irregularly shaped granule, 0.6 g of biodiasmin F-100 was added and mixed to obtain a laxative composition containing lactic acid bacteria.

【0020】実施例3 実施例2で得た不定形顆粒化物120gに水3mlを噴霧
して湿潤させた後、ビオヂアスミンF−100 1.2
gを加えて混合し、直ちに乾燥し、乳酸菌含有瀉下薬組
成物を得た。
Example 3 120 g of the amorphous granule obtained in Example 2 was sprayed with 3 ml of water to wet it, and then Biodiasmin F-100 1.2.
g was added and mixed, and immediately dried to obtain a lactic acid bacterium-containing cathartic composition.

【0021】比較例1 プランタゴ・オバタ種皮100g、及び1.7gのビオ
ヂアスミンF−100を混合機で混合し、乳酸菌含有瀉
下薬組成物を得た。
Comparative Example 1 100 g of plantago ovata seed coat and 1.7 g of biodiasmin F-100 were mixed with a mixer to obtain a laxative composition containing lactic acid bacteria.

【0022】比較例2 プランタゴ・オバタ種皮200g、精製白糖143g及
び3.4gのビオヂアスミンF−100を造粒機(パウ
レック(株)製、FM−VG10型バーチカルグラニュ
レーター)にとり、水40mlを加えて攪拌造粒し、乾燥
した後、整粒し、乳酸菌含有瀉下薬組成物を得た。
Comparative Example 2 200 g of plantago ovata seed coat, 143 g of purified sucrose and 3.4 g of biodiasmin F-100 were taken in a granulator (manufactured by Paulec Co., Ltd., FM-VG10 type vertical granulator), and 40 ml of water was added. After granulating with stirring, drying and sizing, a purgative composition containing lactic acid bacteria was obtained.

【0023】試験例1 実施例1〜3及び比較例1〜2で得た乳酸菌含有瀉下薬
組成物につき、製造時及び40℃で3か月間保存後の乳
酸菌の生菌数を測定した。その結果を表1に示す。
Test Example 1 With respect to the laxative bacterium-containing cathartic compositions obtained in Examples 1 to 3 and Comparative Examples 1 and 2, the number of viable lactic acid bacteria at the time of production and after storage at 40 ° C. for 3 months was measured. Table 1 shows the results.

【0024】[0024]

【表1】 [Table 1]

【0025】表1より明らかなように、本発明によれば
製造時及び40℃で3か月間保存後において乳酸菌の死
滅は認められず安定であった。なお、乳酸菌をプランタ
ゴ・オバタ種皮と共に練合して造粒した比較例2におい
ては製造時に急激な菌の死滅が見られた。
As is clear from Table 1, according to the present invention, lactic acid bacteria were not killed and were stable at the time of production and after storage at 40 ° C. for 3 months. In Comparative Example 2 in which lactic acid bacteria were kneaded together with Plantago ovata seed coat and granulated, abrupt death of the bacteria was observed during production.

【0026】試験例2 実施例1〜3及び比較例1〜2で得た乳酸菌含有瀉下薬
組成物につき、乳酸菌の不定形顆粒化物に対する付着度
を測定した。すなわち、乳酸菌含有瀉下薬組成物10g
を100メッシュ(150μm )の篩にとり、軽くたた
いて、篩を通過した乳酸菌量を求め、非付着率を算出し
た。この結果を表2に示す。
Test Example 2 With respect to the laxative bacterium-containing cathartic compositions obtained in Examples 1 to 3 and Comparative Examples 1 and 2, the degree of adhesion of lactic acid bacterium to an amorphous granule was measured. That is, 10 g of a laxative composition containing lactic acid bacteria
Was put on a 100-mesh (150 μm) sieve and lightly tapped to determine the amount of lactic acid bacteria that passed through the sieve, and the non-adhesion rate was calculated. The results are shown in Table 2.

【0027】[0027]

【表2】 [Table 2]

【0028】表2に示すように、本発明によればプラン
タゴ・オバタ種皮の表面改質により乳酸菌の非付着率は
10%以下に抑えられる。これに対して比較例1ではプ
ランタゴ・オバタ種皮と乳酸菌の混合では付着は不十分
であり、比較例2では乳酸菌はほとんど付着している
が、試験例1で示したように安定性が良くない。
As shown in Table 2, according to the present invention, the non-adherence rate of lactic acid bacteria can be suppressed to 10% or less by the surface modification of the plantago and ovata seed coat. On the other hand, in Comparative Example 1, the adhesion of plantago ovata seed coat and lactic acid bacterium is insufficient, and in Comparative Example 2, lactic acid bacterium is almost adhered, but the stability is not good as shown in Test Example 1. .

【0029】試験例3 実施例1〜3及び比較例1〜2で得た乳酸菌含有瀉下薬
組成物につき、服用感を調べた。この結果を表3に示
す。
Test Example 3 With respect to the laxative bacterium-containing cathartic composition obtained in Examples 1 to 3 and Comparative Examples 1 and 2, the feeling of ingestion was examined. The results are shown in Table 3.

【0030】[0030]

【表3】 [Table 3]

【0031】表3に示すように、本発明による組成物は
服用感に優れており、コンプライアンスの改善に寄与す
るものである。
As shown in Table 3, the composition according to the present invention has an excellent feeling of ingestion and contributes to the improvement of compliance.

【0032】試験例4 試験例1で乳酸菌の安定性の優れていた実施例1、2、
3及び比較例1につきスティック包装し、偏析を調べ
た。すなわち、各乳酸菌含有瀉下薬組成物1.5gずつ
を長さ10cm、幅2cmのスティックにピロ包装したの
ち、1包中の乳酸菌の生菌数を測定し、含量均一性を測
定した。その結果を表4に示した。
Test Example 4 Examples 1 and 2, which were excellent in stability of lactic acid bacteria in Test Example 1,
For 3 and Comparative Example 1, stick packaging was performed and segregation was examined. That is, 1.5 g of each lactic acid bacterium-containing purgative composition was pillo-packed in a stick having a length of 10 cm and a width of 2 cm, and then the viable cell count of the lactic acid bacterium in one package was measured to determine the content uniformity. The results are shown in Table 4.

【0033】[0033]

【表4】 [Table 4]

【0034】本発明によれば、実施例1〜3では乳酸菌
はいずれも均一に分包されており、品質の優れた分包剤
が製造された。特に実施例3においては均一性の高い分
包剤を得ることができた。これに対し、比較例では分包
間のばらつきが見られ、含量均一性は十分では無かっ
た。なお、これらの結果は試験例2で得られた乳酸菌の
付着性と相関するものであった。
According to the present invention, in Examples 1 to 3, the lactic acid bacteria were all uniformly packaged, and a packaging agent having excellent quality was produced. Particularly in Example 3, a packaging material having high uniformity could be obtained. On the other hand, in the comparative example, variation among the packages was observed, and the content uniformity was not sufficient. These results were correlated with the adhesiveness of the lactic acid bacteria obtained in Test Example 2.

Claims (1)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】 プランタゴ・オバタ種皮表面に、水系溶
媒の存在下に糖類を付着せしめて得られた不定形顆粒化
物と乳酸菌とを配合してなる瀉下薬組成物。
1. A laxative composition comprising a lactic acid bacterium and an amorphous granule obtained by adhering a saccharide in the presence of an aqueous solvent on the surface of a plantago / Obata seed coat.
JP5005064A 1993-01-14 1993-01-14 Laxative-containing laxative composition Expired - Fee Related JP2516542B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP5005064A JP2516542B2 (en) 1993-01-14 1993-01-14 Laxative-containing laxative composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5005064A JP2516542B2 (en) 1993-01-14 1993-01-14 Laxative-containing laxative composition

Publications (2)

Publication Number Publication Date
JPH07173068A JPH07173068A (en) 1995-07-11
JP2516542B2 true JP2516542B2 (en) 1996-07-24

Family

ID=11600964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5005064A Expired - Fee Related JP2516542B2 (en) 1993-01-14 1993-01-14 Laxative-containing laxative composition

Country Status (1)

Country Link
JP (1) JP2516542B2 (en)

Also Published As

Publication number Publication date
JPH07173068A (en) 1995-07-11

Similar Documents

Publication Publication Date Title
EP0104167B1 (en) Psyllium compositions
US3138525A (en) Castor wax-amprotropine-resin compositions
JPH02160719A (en) Morphine-containing composition
KR950013752B1 (en) Spray dried acetaminophen
KR950014442B1 (en) Spray dried acetaminophen
US3518344A (en) Tableting lubricant
JPH07242557A (en) Evacuant composition containing lactic acid bacterium
CN1635884A (en) Dry powder formulation comprising racecadotril
WO2005092124A1 (en) Process for producing health food containing dietary fiber
US20160015815A1 (en) Phenylephrine formulations with improved stability
US4950653A (en) Solid iodophor composition
CH636012A5 (en) Pharmacologically acceptable bile acid sequestering agent composition and process for its preparation
US20020150618A1 (en) Process for preparing solid dosage forms of very low-dose drugs
DE60104442T2 (en) NEW GALENIC DISPERSIBLE AND SOLUBLE PARACETAMOL PREPARATION, METHOD FOR ITS PREPARATION AND ITS APPLICATIONS
JP2516542B2 (en) Laxative-containing laxative composition
JP4293572B2 (en) Loxoprofen sodium-containing tablets
JPH11290024A (en) Araliaceous ginseng extract composition
JP2002065213A (en) Method for producing solid agent
EP2037896A1 (en) Effervescent granules or granular material
US10130627B2 (en) Phenylephrine formulations with improved stability
JP3236434B2 (en) Method for producing ginseng extract-containing granules
JP3515954B2 (en) Propolis processed food
JP2864885B2 (en) Nicergoline-containing oral dosage form
JPH0549650B2 (en)
JPH119201A (en) Propolis powder and its production

Legal Events

Date Code Title Description
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 19960220

LAPS Cancellation because of no payment of annual fees